Kaleo

Kaléo is a global leader in drug-delivery device technology and auto-injector innovation. View our Community Guidelines:

[Kaleo @kaleo]

Across the severe allergy landscape, the need for greater awareness and preparedness remains essential. At a time when food allergies are in focus, we’re launching a new initiative centered on real-world experiences. Learn more: https://t.co/qCJX86vzC2

[Kaleo @kaleo]

This Asthma & Allergy Awareness Month, we’re proud to sponsor premiere events for “May Contain,” the award-winning docudrama highlighting the real experiences of children and families navigating food allergies and anaphylaxis.

Learn more: https://t.co/ry0oxYziaz

[Kaleo @kaleo]

Food allergy bullying is more common than many realize & often goes unspoken. As conversations around food allergies continue this May, this episode of The Itch Podcast explores the signs & how to start meaningful conversations with children and schools. https://t.co/81xOIlAg0n

[Kaleo @kaleo]

Food Allergy Awareness Month is here.

FAACT's #InvisibleNoMore campaign offers educational resources and tools to help patients, families, and communities raise awareness of food allergy safety.

Explore the campaign and get involved. https://t.co/Nb9yKFN5wi

[Kaleo @kaleo]

Kaléo’s Medical Affairs team will be attending the Pediatric Academic Societies (PAS) meeting in Boston this April. If you’ll be there, stop by booth 327 to connect.

[Kaleo @kaleo]

The Kaléo team will be at CBRNe Convergence Canada 2026. Attending? Let’s connect about device innovation and real-world usability in critical environments.

[Kaleo @kaleo]

One platform. Three configurations.

The Aerio™ Auto-Injector Platform is designed to meet the highest standards of device function and form while supporting a range of drug delivery needs:
Aerio™Uno
Aerio™Duo
Aerio™Mix

Learn more: https://t.co/KGNk5jYCGe #BuiltToTrust

[Kaleo @kaleo]

One platform. Three configurations.

The Aerio™ Auto-Injector Platform is designed to meet the highest standards of device function and form while supporting a range of drug delivery needs:
Aerio™Uno
Aerio™Duo
Aerio™Mix

Learn more: https://t.co/KGNk5jYCGe #BuiltToTrust

[Kaleo @kaleo]

Recognizing anaphylaxis in infants and toddlers can be challenging since symptoms may look different than in older children. The Recognizing Anaphylaxis in Infants and Toddlers infographic from @AllergyAsthmaHQ outlines what to look for: https://t.co/Tqs5HQfi2B

[Kaleo @kaleo]

Innovation doesn’t start in the lab. It starts with people. From early design to final production, each version of the Aerio™ auto-injector platform is designed to meet the real-world needs of patients and our partners. Learn more: https://t.co/T9LFRZDuHw #BuiltToTrust

[Kaleo @kaleo]

@AllergyAsthmaHQ Grateful to collaborate with you in support of this important work.

[Kaleo @kaleo]

We’re looking forward to connecting with the allergy and immunology community and being part of the important conversations taking place around research, education, and patient care.

If you’re attending, we hope to see you there! #AAAAI26

[Kaleo @kaleo]

25 years of Kaléo.

Since 2000, our mission has focused on providing patients with the security and peace of mind that can only come when human ingenuity precisely meets human need. Read more: https://t.co/PuqCCqBENk #BuiltToTrust

[Kaleo @kaleo]

Our MCM team is heading to Lyon for Intelligence-SEC CBRNe Summit Europe 2026 from February 3-5. Come visit us at the booth to learn more about our medical countermeasure capabilities. https://t.co/jhoO5h6wSB

[Kaleo @kaleo]

Great to see Kaléo highlighted in European Security & Defence Magazine for our role in advancing medical countermeasures that support CBRN preparedness. Read the article: https://t.co/sxrGvXkWeC

[Kaleo @kaleo]

Leadership update: Kaléo welcomes Ram Halthore as VP, Development, joining Carrie Siragusa, CPA, VP, Marketing & PR - strengthening our focus on innovation, growth, and preparedness. Full announcement: https://t.co/BPdd0qt37D

[Kaleo @kaleo]

Kaléo’s Aerio™ platform is built for real-world needs, supporting large-volume and high-viscosity formulations with a compact, easy-to-use design. Learn more: https://t.co/T9LFRZDuHw

[Kaleo @kaleo]

In 2026, Kaléo remains committed to advancing solutions that protect and empower communities worldwide. Wishing you a year of progress, health, and possibility.

[Kaleo @kaleo]

As 2025 wraps up, we’re proud to support the Early Childhood Anaphylaxis Collaborative & excited for what’s ahead in 2026. Join today to help shape what's next & support early childcare centers in managing anaphylaxis: https://t.co/dnOe8Vme3e #ECACollaborativePartner #childcare

[Kaleo @kaleo]

Honored to celebrate the Elijah-Alavi Foundation @Elijahsecho at yesterday’s NYC bill signing. The new legislation builds on Elijah’s Law to expand access to weight-based epinephrine and staff training in all city schools and childcare programs.